フォン・ヴィレブランド病の世界市場レポート 2025年

フォン・ヴィレブランド病市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR7.2％で24億8,000万米ドルに成長します。予測期間中の成長予測は、出血性疾患に対する遺伝子治療の開発増加、バイオテクノロジー研究への投資増加、非侵襲的診断技術への需要増加、疾患モニタリングのためのデジタルヘルスツールの使用増加、希少疾患に対する遠隔医療サービスの拡大などの要因によるものと考えられます。この期間の主な動向としては、遺伝子治療アプローチの発展、診断における人工知能の統合、非侵襲的診断ツールの革新、新規ドラッグデリバリーシステムの導入、患者教育のためのデジタルヘルスプラットフォームの開発などが挙げられます。

出血性疾患の有病率の増加は、フォン・ヴィレブランド病市場の成長を促進すると予想されます。出血性疾患とは、体内で血栓を形成する能力が損なわれ、出血が長引いたり過剰になったりする病状を指します。出血性疾患と診断される症例の増加は、医療知識と診断ツールの進歩により、ヘルスケア専門家が以前は気づかなかった病態を発見できるようになったことに起因しています。フォン・ヴィレブランド病の治療は、血液凝固を改善し、過剰な出血を最小限に抑え、患者全体の生活の質を高めることで患者を助ける。例えば、英国血友病センター医師団体の報告によると、英国における血友病Aの新規登録数は2021年の16人から2022年には19人に増加したことが明らかになりました。このような出血性疾患に対する認識と診断の高まりが、フォン・ヴィレブランド病市場の拡大に寄与しています。

フォン・ヴィレブランド病市場の主要企業は、治療効果の向上、出血エピソードの減少、患者の転帰の改善を目的として、フォン・ヴィレブランド因子（VWF）濃縮製剤などの革新的な治療法の開発に注力しています。VWF濃縮製剤は、フォン・ヴィレブランド因子の欠乏または機能不全によって引き起こされるフォン・ヴィレブランド病患者の出血を治療および予防するために使用される薬剤です。例えば、2024年4月、米国の製薬会社であるOctapharma USA Inc.は、VWF濃縮製剤であるWilateが米国食品医薬品局（FDA）から承認されたと発表しました。ウィラテは静脈注射用の凍結乾燥粉末溶液で、成人および6歳以上の小児の出血エピソードの頻度を減らすための定期的な予防に使用されます。FDAはウィラテに希少疾病用医薬品の指定を与え、希少疾病の治療開発を奨励するために最大7年間の市場独占権を与えました。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界のフォン・ヴィレブランド病 PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のフォン・ヴィレブランド病市場：成長率分析
• 世界のフォン・ヴィレブランド病市場の実績：規模と成長, 2019-2024
• 世界のフォン・ヴィレブランド病市場の予測：規模と成長, 2024-2029, 2034F
• 世界のフォン・ヴィレブランド病総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のフォン・ヴィレブランド病市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• タイプ1
• タイプ2
• タイプ3
• 世界のフォン・ヴィレブランド病市場：薬物別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 抗血友病因子
• 凝固因子VIII複合体
• フォン・ヴィレブランド因子
• デスモプレシン酢酸塩
• その他の薬物
• 世界のフォン・ヴィレブランド病市場：重症度別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 軽度
• 中程度
• 重度
• 世界のフォン・ヴィレブランド病市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• オンライン薬局
• その他の流通チャネル
• 世界のフォン・ヴィレブランド病市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 専門クリニック
• ホームケア
• その他のエンドユーザー
• 世界のフォン・ヴィレブランド病市場：タイプ別サブセグメンテーション、タイプ1、実績と予測, 2019-2024, 2024-2029F, 2034F
• 軽度のフォン・ヴィレブランド病
• 中程度のフォン・ヴィレブランド病
• 重度のフォン・ヴィレブランド病
• 世界のフォン・ヴィレブランド病市場：タイプ別サブセグメンテーション、タイプ2、実績と予測, 2019-2024, 2024-2029F, 2034F
• タイプ2A
• タイプ2B
• タイプ2M
• タイプ2N
• 世界のフォン・ヴィレブランド病市場：タイプ別サブセグメンテーション、タイプ3、実績と予測, 2019-2024, 2024-2029F, 2034F
• 先天性3型
• 後天性3型

第7章 地域別・国別分析

• 世界のフォン・ヴィレブランド病市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のフォン・ヴィレブランド病市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• フォン・ヴィレブランド病市場：競合情勢
• フォン・ヴィレブランド病市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis
  • Novo Nordisk A/S Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Mayo Clinic
• CSL Behring（a subsidiary of CSL Limited）
• Cleveland Clinic
• Grifols S.A.
• Kedrion Biopharma Inc.
• Shanghai RAAS Blood Products Co. Ltd.
• Biotest AG
• Versiti Inc.
• Fortis Healthcare Limited
• LFB S.A.
• Hualan Biological Engineering Inc.
• Bio Products Laboratory Ltd.（BPL）
• Octapharma AG
• Sino Biological Inc.
• Reliance Life Sciences Pvt. Ltd.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• フォン・ヴィレブランド病市場2029：新たな機会を提供する国
• フォン・ヴィレブランド病市場2029：新たな機会を提供するセグメント
• フォン・ヴィレブランド病市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Von Willebrand disease (VWD) is a genetic bleeding disorder caused by a deficiency or dysfunction of von Willebrand factor (VWF), a protein that plays a crucial role in blood clotting. The severity of the disorder depends on the amount and functionality of von Willebrand factor in the blood.

The main types of von Willebrand disease include type 1, type 2, and type 3. Type 1 is a mild form of the disorder, where individuals have lower-than-normal levels of von Willebrand factor, leading to difficulties in proper blood clotting. The drugs used to manage VWD include antihemophilic factor, coagulation factor VIII complex, von Willebrand factor, desmopressin acetate, and others, with severity levels ranging from mild to severe. These treatments are distributed through various channels, including hospital pharmacies, retail pharmacies, online pharmacies, and others. They are used by a variety of end-users, such as hospitals, specialty clinics, homecare providers, and others.

The von willebrand disease market research report is one of a series of new reports from The Business Research Company that provides von willebrand disease market statistics, including von willebrand disease industry global market size, regional shares, competitors with a von willebrand disease market share, detailed von willebrand disease market segments, market trends and opportunities, and any further data you may need to thrive in the von willebrand disease industry. This von willebrand disease market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The von willebrand disease market size has grown strongly in recent years. It will grow from $1.74 billion in 2024 to $1.88 billion in 2025 at a compound annual growth rate (CAGR) of 7.6%. The growth during the historic period can be attributed to several factors, including increased awareness of rare bleeding disorders, higher diagnosis rates of von Willebrand disease, growth in research funding for blood disorders, improved access to healthcare, and a rising use of prophylactic treatments in hemophilia care.

The von willebrand disease market size is expected to see strong growth in the next few years. It will grow to $2.48 billion in 2029 at a compound annual growth rate (CAGR) of 7.2%. The projected growth during the forecast period can be attributed to factors such as the increasing development of gene therapies for bleeding disorders, rising investment in biotechnology research, a growing demand for non-invasive diagnostic techniques, the increasing use of digital health tools for disease monitoring, and the expansion of telemedicine services for rare diseases. Key trends for this period include advancements in gene therapy approaches, the integration of artificial intelligence in diagnostics, innovations in non-invasive diagnostic tools, the introduction of novel drug delivery systems, and the development of digital health platforms for patient education.

The increasing prevalence of bleeding disorders is expected to drive the growth of the von Willebrand disease market. Bleeding disorders refer to medical conditions that impair the body's ability to form blood clots, resulting in prolonged or excessive bleeding. The rise in diagnosed cases of bleeding disorders can be attributed to advancements in medical knowledge and diagnostic tools, which have enabled healthcare professionals to detect conditions that previously went unnoticed. Treatments for von Willebrand disease help patients by improving blood clotting, minimizing excessive bleeding, and enhancing their overall quality of life. For example, a report from the United Kingdom Haemophilia Centre Doctors' Organization revealed that new registrations of Hemophilia A in the UK increased from 16 in 2021 to 19 in 2022. This growing awareness and diagnosis of bleeding disorders are contributing to the expansion of the von Willebrand disease market.

Key players in the von Willebrand disease market are focusing on developing innovative treatments, such as von Willebrand factor (VWF) concentrate, to improve treatment effectiveness, reduce bleeding episodes, and enhance patient outcomes. VWF concentrate is a medication used to treat and prevent bleeding in patients with von Willebrand disease, which is caused by a deficiency or dysfunction of the von Willebrand factor. For instance, in April 2024, Octapharma USA Inc., a US-based pharmaceutical company, announced that Wilate, a VWF concentrate, had been approved by the U.S. Food and Drug Administration (FDA). Wilate is a lyophilized powder solution for intravenous injection used for routine prophylaxis to reduce the frequency of bleeding episodes in both adults and children aged six and older. The FDA granted Wilate orphan drug designation, providing it with up to seven years of market exclusivity to encourage the development of treatments for rare diseases.

In January 2024, Takeda Pharmaceutical Company, based in Japan, acquired Shire plc. for $62 billion. This acquisition aims to strengthen Takeda's position in rare diseases, plasma-derived therapies, and hematology, including treatments for von Willebrand disease and other bleeding disorders. Shire plc, a UK-based biotechnology company, focuses on developing therapies for rare diseases, including von Willebrand disease.

Major players in the von willebrand disease market are Pfizer Inc., Bayer AG, Sanofi S.A., Takeda Pharmaceutical Company Limited, Novo Nordisk A/S, Mayo Clinic, CSL Behring (a subsidiary of CSL Limited), Cleveland Clinic, Grifols S.A., Kedrion Biopharma Inc., Shanghai RAAS Blood Products Co. Ltd., Biotest AG, Versiti Inc., Fortis Healthcare Limited, LFB S.A., Hualan Biological Engineering Inc., Bio Products Laboratory Ltd. (BPL), Octapharma AG, Sino Biological Inc., Reliance Life Sciences Pvt. Ltd.

North America was the largest region in the von willebrand disease market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in von willebrand disease report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the von willebrand disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The von willebrand disease market consists of sales of antifibrinolytic drugs, harmonal therapy, and clotting factor concentrates. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Von Willebrand Disease Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on von willebrand disease market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for von willebrand disease ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The von willebrand disease market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Type 1; Type 2; Type 3
• 2) By Drugs: Antihemophilic Factor; Coagulation Factor VIII Complex; Von Willebrand Factor; Desmopressin Acetate; Other Drugs
• 3) By Severity: Mild; Moderate; Severe
• 4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy; Other Distribution Channels
• 5) By End Users: Hospitals; Speciality Clinics; Homecare; Other End Users
• Sub Segments:
• 1) By Type 1: Mild Von Willebrand Disease; Moderate Von Willebrand Disease; Severe Von Willebrand Disease
• 2) By Type 2: Type 2A; Type 2B; Type 2M; Type 2N
• 3) By Type 3: Congenital Type 3; Acquired Type 3
• Companies Mentioned: Pfizer Inc.; Bayer AG; Sanofi S.A.; Takeda Pharmaceutical Company Limited; Novo Nordisk A/S
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Von Willebrand Disease Market Characteristics

3. Von Willebrand Disease Market Trends And Strategies

4. Von Willebrand Disease Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Von Willebrand Disease Growth Analysis And Strategic Analysis Framework

• 5.1. Global Von Willebrand Disease PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Von Willebrand Disease Market Growth Rate Analysis
• 5.4. Global Von Willebrand Disease Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Von Willebrand Disease Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Von Willebrand Disease Total Addressable Market (TAM)

6. Von Willebrand Disease Market Segmentation

• 6.1. Global Von Willebrand Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Type 1
• Type 2
• Type 3
• 6.2. Global Von Willebrand Disease Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antihemophilic Factor
• Coagulation Factor VIII Complex
• Von Willebrand Factor
• Desmopressin Acetate
• Other Drugs
• 6.3. Global Von Willebrand Disease Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Mild
• Moderate
• Severe
• 6.4. Global Von Willebrand Disease Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Other Distribution Channels
• 6.5. Global Von Willebrand Disease Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Speciality Clinics
• Homecare
• Other End Users
• 6.6. Global Von Willebrand Disease Market, Sub-Segmentation Of Type 1, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Mild Von Willebrand Disease
• Moderate Von Willebrand Disease
• Severe Von Willebrand Disease
• 6.7. Global Von Willebrand Disease Market, Sub-Segmentation Of Type 2, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Type 2A
• Type 2B
• Type 2M
• Type 2N
• 6.8. Global Von Willebrand Disease Market, Sub-Segmentation Of Type 3, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Congenital Type 3
• Acquired Type 3

7. Von Willebrand Disease Market Regional And Country Analysis

• 7.1. Global Von Willebrand Disease Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Von Willebrand Disease Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Von Willebrand Disease Market

• 8.1. Asia-Pacific Von Willebrand Disease Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Von Willebrand Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Von Willebrand Disease Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Von Willebrand Disease Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Von Willebrand Disease Market

• 9.1. China Von Willebrand Disease Market Overview
• 9.2. China Von Willebrand Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Von Willebrand Disease Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Von Willebrand Disease Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Von Willebrand Disease Market

• 10.1. India Von Willebrand Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Von Willebrand Disease Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Von Willebrand Disease Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Von Willebrand Disease Market

• 11.1. Japan Von Willebrand Disease Market Overview
• 11.2. Japan Von Willebrand Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Von Willebrand Disease Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Von Willebrand Disease Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Von Willebrand Disease Market

• 12.1. Australia Von Willebrand Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Von Willebrand Disease Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Von Willebrand Disease Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Von Willebrand Disease Market

• 13.1. Indonesia Von Willebrand Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Von Willebrand Disease Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Von Willebrand Disease Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Von Willebrand Disease Market

• 14.1. South Korea Von Willebrand Disease Market Overview
• 14.2. South Korea Von Willebrand Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Von Willebrand Disease Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Von Willebrand Disease Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Von Willebrand Disease Market

• 15.1. Western Europe Von Willebrand Disease Market Overview
• 15.2. Western Europe Von Willebrand Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Von Willebrand Disease Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Von Willebrand Disease Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Von Willebrand Disease Market

• 16.1. UK Von Willebrand Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Von Willebrand Disease Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Von Willebrand Disease Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Von Willebrand Disease Market

• 17.1. Germany Von Willebrand Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Von Willebrand Disease Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Von Willebrand Disease Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Von Willebrand Disease Market

• 18.1. France Von Willebrand Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Von Willebrand Disease Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Von Willebrand Disease Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Von Willebrand Disease Market

• 19.1. Italy Von Willebrand Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Von Willebrand Disease Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Von Willebrand Disease Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Von Willebrand Disease Market

• 20.1. Spain Von Willebrand Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Von Willebrand Disease Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Von Willebrand Disease Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Von Willebrand Disease Market

• 21.1. Eastern Europe Von Willebrand Disease Market Overview
• 21.2. Eastern Europe Von Willebrand Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Von Willebrand Disease Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Von Willebrand Disease Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Von Willebrand Disease Market

• 22.1. Russia Von Willebrand Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Von Willebrand Disease Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Von Willebrand Disease Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Von Willebrand Disease Market

• 23.1. North America Von Willebrand Disease Market Overview
• 23.2. North America Von Willebrand Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Von Willebrand Disease Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Von Willebrand Disease Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Von Willebrand Disease Market

• 24.1. USA Von Willebrand Disease Market Overview
• 24.2. USA Von Willebrand Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Von Willebrand Disease Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Von Willebrand Disease Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Von Willebrand Disease Market

• 25.1. Canada Von Willebrand Disease Market Overview
• 25.2. Canada Von Willebrand Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Von Willebrand Disease Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Von Willebrand Disease Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Von Willebrand Disease Market

• 26.1. South America Von Willebrand Disease Market Overview
• 26.2. South America Von Willebrand Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Von Willebrand Disease Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Von Willebrand Disease Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Von Willebrand Disease Market

• 27.1. Brazil Von Willebrand Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Von Willebrand Disease Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Von Willebrand Disease Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Von Willebrand Disease Market

• 28.1. Middle East Von Willebrand Disease Market Overview
• 28.2. Middle East Von Willebrand Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Von Willebrand Disease Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Von Willebrand Disease Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Von Willebrand Disease Market

• 29.1. Africa Von Willebrand Disease Market Overview
• 29.2. Africa Von Willebrand Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Von Willebrand Disease Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Von Willebrand Disease Market, Segmentation By Severity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Von Willebrand Disease Market Competitive Landscape And Company Profiles

• 30.1. Von Willebrand Disease Market Competitive Landscape
• 30.2. Von Willebrand Disease Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Novo Nordisk A/S Overview, Products and Services, Strategy and Financial Analysis

31. Von Willebrand Disease Market Other Major And Innovative Companies

• 31.1. Mayo Clinic
• 31.2. CSL Behring (a subsidiary of CSL Limited)
• 31.3. Cleveland Clinic
• 31.4. Grifols S.A.
• 31.5. Kedrion Biopharma Inc.
• 31.6. Shanghai RAAS Blood Products Co. Ltd.
• 31.7. Biotest AG
• 31.8. Versiti Inc.
• 31.9. Fortis Healthcare Limited
• 31.10. LFB S.A.
• 31.11. Hualan Biological Engineering Inc.
• 31.12. Bio Products Laboratory Ltd. (BPL)
• 31.13. Octapharma AG
• 31.14. Sino Biological Inc.
• 31.15. Reliance Life Sciences Pvt. Ltd.

32. Global Von Willebrand Disease Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Von Willebrand Disease Market

34. Recent Developments In The Von Willebrand Disease Market

35. Von Willebrand Disease Market High Potential Countries, Segments and Strategies

• 35.1 Von Willebrand Disease Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Von Willebrand Disease Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Von Willebrand Disease Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer